Sort
48,018 grants matching “immunotherapy”
CXCR4 ANTAGONIST AS AN ADJUVANT IN IMMUNOTHERAPY OF EPITHELIAL OVARIAN CANCER
$771,750Health Research, Inc. · · FY2016 · Department of the Army
Mechanisms and manipulation of force dependent behavior in T cell biology
$771,569Brian M Baker · University Of Notre Dame · R01 · FY2023 · AI
Decoding and reprogramming T cells through synthetic biology for cancer immunotherapy
$771,499Alexander Marson · J. David Gladstone Institutes · R01 · FY2023 · CA
Brain myeloid cell-targeted multiplexed gene editing for SIV/HIV eradication
$771,175Binhua Ling · Texas Biomedical Research Institute · R01 · FY2025 · MH
Data and Resource Coordination Center for Cancer Prevention-Interception Targeted Agent Discovery Program
$771,165Alan David Hutson · Roswell Park Cancer Institute Corp · U24 · FY2023 · CA
Engineering T cells to Promote Islet Transplant
$771,158James L Riley · University Of Pennsylvania · R01 · FY2025 · DK
Adoptive T cell Therapy for Pediatric Leukemia
$771,137Terry Fry · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Personal tumor neoantigens for immunity against chronic lymphocytic leukemia
$771,133Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2022 · CA
Clinical Trials of Immunotherapies for Childhood Cancer
$770,902Crystal Mackall · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors
$770,888Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA
HIV-specific ex-vivo expanded T cell therapy (HXTC) to Deplete the Latent Reservoir of Persistent HIV Infection
$770,866David M. Margolis · Univ Of North Carolina Chapel Hill · R01 · FY2017 · HL
Immunobiology of Normal and Neoplastic Lymphocytes
$770,728Warren S Pear · University Of Pennsylvania · T32 · FY2024 · CA
Allergen T cell epitopes and phenotypes in peanut allergy
$770,650William W. Kwok · Benaroya Research Inst At Virginia Mason · U19 · FY2019 · AI
COPD Clinical Research Network
$770,300University Of California San Francisco · U10 · FY2003 · HL
Enhancing Susceptibility of HIV Reservoirs to CTL Through a Discovery to Translational Approach
$770,236R. Brad Jones · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · AI
TOLERANCE TO ISLET ALLOGRAFTS IN TYPE I DIABETES
$769,979University Of Minnesota Twin Cities · R01 · FY2000 · DK
Vascular macrophages and T cells in atherosclerosis
$769,886Klaus F. Ley · Augusta University · R35 · FY2025 · HL
Mechanisms of Chronic Hepatitis B Infection and Therapeutic Vaccines
$769,814David R. Milich · Vaccine Research Institute Of San Diego · R01 · FY2009 · AI
Vascular macrophages and T cells in atherosclerosis
$769,654Klaus F. Ley · Augusta University · R35 · FY2023 · HL
Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas
$769,404Joana M Murad · Celdara Medical, Llc · R44 · FY2023 · CA
B cell-dependent anti-tumor immunity in ovarian cancer
$769,358Jose R Conejo-Garcia · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2020 · CA
Generation of highly differentiated NK cells to synergize with broadly neutralizing antibodies to establish viral control in absence of ART
$769,220Mirko Paiardini · Emory University · R01 · FY2025 · AI
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell Therapy
$768,857Vladimir Ponomarev · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA
Characteristics and protective efficacy of human antibodies against M. tuberculosis
$768,623Jacqueline Michele Achkar · Albert Einstein College Of Medicine · R01 · FY2020 · AI
CLINICAL TRIALS USING TCR TRANSDUCED T CELL FOR ADOPTIVE IMMUNOTHERAPY
$768,601Michael I Nishimura · Loyola University Chicago · P01 · FY2015 · CA